摘要
目的观察补肾清透方治疗慢性乙型肝炎(CHB)e抗原阳性患者外周血中HBV载量和T淋巴细胞亚群的变化。方法60例慢性乙型肝炎e抗原阳性患者被随机分成CHB治疗组和CHB对照组,每组30例,CHB治疗组接受补肾清透方治疗,疗程48周,CHB对照组不接受药物治疗;同时选择30例健康人作为健康人对照组。第48周时CHB患者抽血检查T淋巴细胞亚群和HBV DNA载量以及肝功能,健康人对照组检测T淋巴细胞亚群。结果CHB对照组与健康人对照组相比,CD4+、CD4+/CD8+显著下降,CD8+显著升高(P<0.01),CD3+变化不明显(P>0.05);CHB治疗组与CHB对照组比较,CD4+、CD4+/CD8+显著升高,CD8+,HBV载量显著下降(P<0.01),CD3+变化不明显(P>0.05)。结论补肾清透方能抑制CHB e抗原阳性患者HBVDNA复制,提高机体的免疫功能。
Objective To observe the changes of HBV load in peripheral blood and T-lymphocyte subsets in chronic hepatitis B(CHB) patients with positive e-antigen after treated with the Bushen Qingtou Prescription.Methods A total of 60 cases of CHB patients with positive e-antigen were randomly divided into two groups: the treatment group and the control group,with 30 cases in each group.During the 48-week treatments,Bushen Qingtou Prescription was applied to all the patients in the treatment group,but no treatment was used in the control group.Thirty healthy volunteers were selected as healthy control group.At the 48th week,blood samples were taken from all the 60 subjects for the tests of T-lymphocyte subsets,load of HBV DNA and liver function,and the samples from 30 healthy subjects were only tested for their T-lymphocyte subsets.Results Compared with the cases in the healthy control group,the contents of CD4+,CD4+/CD8+ in the CHB control group were remarkably decreased,and the level of CD8+ was obviously increased(P0.01).However,the content of CD3+ didn't change apparently(P0.05).Compared with the cases in the CHB control group,the contents of CD4+,CD4+/CD8+ in the CHB treatment group were remarkably increased,the levels of CD8+ and the HBV load were obviously decreased(P0.01).However,the content of CD3+ didn't change apparently(P0.05).Conclusion Bushen Qingtou Prescription could inhibit the replication of HBV DNA in the CHB patients with positive e-antigen and improve the immune function of body.
出处
《实验与检验医学》
CAS
2012年第2期163-165,171,共4页
Experimental and Laboratory Medicine
基金
深圳市科技计划项目(医疗卫生类
编号20113387)